DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/m427tb/competitive) has announced the addition of the "Competitive Handbook towards Personalized Medicine in Prostate Cancer" report to their offering.
BioSeeker builds its analysis on a comprehensive base of 394 prostate cancer drugs from within the portfolio of 222 companies world-wide, from Ceased to Marketed. We have identified 227 drug targets, which we have organized into 216 drug target strategies, and assessed them by four levels:
1. Individual Target: Shows you how individual targets tie into different target strategies and their subsequent R&D progress.
2. Developmental Stage: Shows you the progress and maturation of different target strategies. Identifies which target strategies are new and unique from one developmental stage to the next.
3. Compound Type: Shows you the competitive landscape of target strategies from a compound perspective, including crossover analysis of target strategies among different compound types.
4. Company: Provides a cross-examination of each company's entire pipeline on the basis of its defined drug target strategies, including a Competitive Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.
Companies Mentioned:
Abbott
Active Biotech
Advantagene
Egera
Eterna Zentaris
lchemia
Alethia Biotherapeutics
Allos Therapeutics
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambrilia Biopharma
American Gene Technology International
Amgen
Anavex Life Sciences
AndroBioSys
Biostar
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Camurus
Cancer Research Technology
Cel-Sci
Celgene
Curaxis
Curis
Cylene Pharmaceuticals
Cytokinetics
Daiichi Sankyo
Debiopharm
Dendreon
Dongkook Pharm
ECI
Eisai
Eli Lilly
Endo Pharmaceuticals
Endocyte
Ensemble Discovery
EntreMed
EpiCept
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Ferring
Formula Pharmaceuticals
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
Got-a-Gene
GP Pharm
Green Cross
GTx
Harbor BioSciences
Hoffmann-La Roche
Human Genome Sciences
IGF Oncology
Immunocore
ImmunoGen
Isis Pharmaceuticals
Ivy Medical Chemicals
Johnson & Johnson
Karo Bio
Kinex
Kyowa Hakko Kirin
Leo
Ligand
Lorus Therapeutics
MediGene
Nippon Shinyaku
Non-industrial Sources
Northwest Biotherapeutics
Novacea
Novartis
Oncothyreon
Oncovir
Orion Pharma
Paladin Labs
Pantarhei Bioscience
Pepscan Therapeutics
Pfizer
ProStrakan
Q Chip
QLT
Receptor BioLogix
Regeneron
Regulon
Rexahn
SGX Pharmaceuticals
Shire
Siena Biotech
Soligenix
Sophiris Bio
SRI International
Supratek Pharma
Switch Pharma
Synta Pharmaceuticals
Taiho
Takeda
Tapestry Pharmaceuticals
Twinstrand Therapeutics
Unigene
United Biomedical
Vaxon Biotech
Velacor Therapeutics
Xerion
Xoma
YM BioSciences
Zydus Cadila
For more information visit http://www.researchandmarkets.com/research/m427tb/competitive
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Prostate Cancer
Source: Research and Markets